# P473 Comparison of clinical performance of fecal calprotectin of laboratory methods with lateral flow based POC and home tests

## Christian Reinhard, Marie-Eve Ueberschlag, Daniela Trapani-Vondran, Sabine Kräuchi, Romain Pénager, Peter Kupchak, Thomas Schuster

**BÜHLMANN Laboratories AG, Schönenbuch, Switzerland**

correspondence: cre@buhlmannlabs.ch

## INTRODUCTION

To confirm an IBD diagnosis and manage IBD patients, endoscopy is the gold standard to assess mucosal inflammation. Fecal calprotectin (fCAL) is a reliable biomarker of intestinal inflammation that highly correlates with endoscopic and histological findings. Fecal calprotectin testing is recommended in most IBD guidelines for diagnosis and disease course evaluation. Different assay technologies exist that need to measure fecal calprotectin comparably. These range from classic enzyme linked immunosorbent assays (ELISA), particle enhance turbidimetric immuno assays (PETIA), and rapid lateral flow immuno assays (LFIA). LFIAs can be read by conventional tabletop readers or by everyday smartphone applications using the phone's camera to acquire an image of the test cassette and calculate a quantitative result based on Test and Control line intensity. As there is no international standard to date, fecal calprotectin assay manufacturers rely on their own internal calprotectin standardization. This study compared four different assays measuring the same clinical samples.

## METHODS

We measured 128 raw stool samples from an FDA submission study[1] obtained from patients that presented with signs and symptoms suggesting intestinal inflammation and underwent endoscopic evaluation to establish or exclude an IBD diagnosis. Samples were extracted with the BÜHLMANN CALEX® Cap stool preparation device. Each extract was then measured on the BÜHLMANN fCAL® ELISA (fCAL ELISA), BÜHLMANN fCAL® turbo (fCAL turbo), Quantum Blue® fCAL extended (QB fCAL) and the smartphone based IB*Doc*® fCAL home test. For the home test, two phones, iPhone 11 and Samsung Galaxy S7, were used to measure the test cassettes. Each sample was measured one time on each assay and Receiver Operating Characteristic (ROC) curve analysis was performed and total agreement between each method was calculated.

## RESULTS

ROC curves were generated to assess the ability of each assay to differentiate between IBS and IBD with area under the curve (AUC) values ranging from 0.827 (Samsung Galaxy S7) to 0.835 (fCAL turbo). There was no significant difference between the methods (Figure 1). BÜHLMANN recommends cut-offs at 80 µg/g and 160 µg/g for IBS/IBD differentiation and 100 µg/g and 300 µg/g for IBD monitoring. For all methods, the sensitivity at the cut-off level 80 µg/g was 90.8 % and specificity at 160 µg/g ranged from 67.3% to 82.2%. Sensitivity at a cut-off of 100 µg/g ranged from 85.5% to 88.2% and specificity at 300 µg/g ranged from 87.2% to 86.5% (Table 1). In addition to a cut-off at 300 µg/g, 250 µg/g is also a commonly used level in the assessment of IBD patients. Positive and negative percent agreement (PPA/NPA) between the smartphone-based home test and the BÜHLMANN fCAL® turbo and Quantum Blue® fCAL extended lateral flow assay were calculated for values in the measuring range of the assays. The PPA was above 90% and the NPA was above 88% for all methods.



**Figure 1:** Receiver Operating Characteristic (ROC) Curve Analysis for different fecal calprotectin methods.

| | IBDoc (iPhone 11) | IBDoc (Samsung S7) | QB fCAL | fCAL turbo | fCAL ELISA |
|---|---|---|---|---|---|
| **Sensitivity at 80 µg/g** | 90.8% | 90.8% | 90.8% | 90.8% | 90.8% |
| **Specificity at 160 µg/g** | 71.2% | 82.7% | 71.2% | 71.2% | 67.3% |
| **Sensitivity at 100 µg/g** | 86.8% | 88.2% | 88.2% | 85.5% | 88.2% |
| **Specificity at 300 µg/g** | 84.6% | 82.7% | 84.6% | 86.5% | 84.6% |

**Table 1:** Sensitivity and specificity for the IBS/IBD differentiation cut-offs (80/160 µg/g) and the IBD monitoring cut-offs (100/300 µg/g) of different fecal calprotectin methods are shown.

| | Estimate of Percent Agreement between IBDoc and fCAL turbo | | Estimate of Percent Agreement between IBDoc and QB fCAL | |
|---|---|---|---|---|
| | iPhone 11 | Samsung S7 | iPhone 11 | Samsung S7 |
| **PPA at 100 µg/g** | 120/127 = 94.5% | 121/126 = 96.0% | 127/132 = 96.2% | 128/131 = 97.7% |
| **NPA at 100 µg/g** | 89/97 = 91.8% | 86/97 = 88.7% | 91/92 = 98.9% | 88/92 = 95.7% |
| **PPA at 250 µg/g** | 72/75 = 96.0% | 71/74 = 95.9% | 73/75 = 97.3% | 73/74 = 98.6% |
| **NPA at 250 µg/g** | 146/149 = 98.0% | 142/149 = 95.3% | 147/149 = 98.7% | 144/149 = 96.9% |

**Table 2:** Estimates of PPA and NPA between IB*Doc*® results and corresponding Quantum Blue® fCAL and fCAL turbo assay results.

## CONCLUSION

The results presented here show that the four BÜHLMANN assays measure fecal calprotectin highly comparably and show an excellent clinical performance. This allows for the use of the methods interchangeably, depending on the needs of the patients and their care team.

[1]Berinstein, J.A. *et al.*, 2019, The Clinical Accuracy of the BÜHLMANN fCAL ELISA in the Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome: A Multicenter Prospective Case-Control Study, Crohn's & Colitis

BÜHLMANN